Ipilimumab in patients with melanoma and autoimmune disease

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  Kyi, Chrisann ^a   Carvajal, Richard D ^b,c   Wolchok, Jedd D ^b,c   Postow, Michael A ^b,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autoimmune diseases; Immune related adverse events (irAEs); Immunotherapy; Ipilimumab; Melanoma; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

BETA INTERFERON; CARBOPLATIN; CELECOXIB; CISPLATIN; GAMMA SECRETASE INHIBITOR; IPILIMUMAB; METHOTREXATE; PACLITAXEL; PREDNISONE; TEMOZOLOMIDE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; FATIGUE; FECES INCONTINENCE; FEMALE; HUMAN; HUMAN TISSUE; INGUINAL REGION; JOINT EFFUSION; KNEE PAIN; LOW DRUG DOSE; MALE; MELANOMA; MIDDLE AGED; MULTIPLE SCLEROSIS; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN NODULE; TREATMENT RESPONSE; TUMOR GROWTH; URINE INCONTINENCE; WEIGHT REDUCTION;

EID: 84977136814     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0035-z     Document Type: Article

References (13)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Yellin TJ, Nichol GM, Axel HA, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723. 10.1056/NEJMoa1003466, 20525992.
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain J, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Michal Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526. 10.1056/NEJMoa1104621, 21639810.
3. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and Anti-PD-1. Front Immunol 2014, 5:206. 10.3389/fimmu.2014.00206, 24904570.
4. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30(21):2691-2697. 10.1200/JCO.2012.41.6750, 22614989.
5. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996, 184(2):783-788. 10.1084/jem.184.2.783, 8760834.
6. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996, 157(4):1333-1336. 8759711.
7. Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001, 166(10):6430-6436. 10.4049/jimmunol.166.10.6430, 11342669.
8. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998, 187(3):427-432. 10.1084/jem.187.3.427, 9449722.
9. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58(6):840-846. 10.1002/ana.20703, 16283615.
10. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008, 26(14):2299-2304. 10.1200/JCO.2007.14.5292, 18467721.
11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69(9):1580-1588. 10.1136/ard.2010.138461, 20699241.
12. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014, 32(19):e69-e71. 10.1200/JCO.2013.49.2314, 24493726.
13. Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012, 87(10):991-1003. 10.1016/j.mayocp.2012.04.018, 23036673.